Potent inhibitor of PARP-1 and PARP-2 (potency ≤5 nM in vitro).
An antineoplastic antibiotic. Inhibits DNA-primed RNA polymerase by complexing with DNA via deoxyguanosine residues.
A solution (2 mg/ml) of the antineoplastic antibiotic in anhydrous DMSO.
A specific, irreversible serine protease inhibitor. Inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin and trypsin. A stable, non-toxic and better soluble alternative to PMSF.
AG-1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor.
SC79 is a specific and BBB permeable Akt activator that activates Akt in the cytosol and inhibits Akt membrane translocation.
A potent thiadiazolyl analog that binds to PH (pleckstrin homology) domain (Kd = 40.8 µM, Ki = 2.4 µM)..
A cell-permeable compound that directly and reversibly interacts with miRNA binding domain of Argonaute-2 (Kd = 126 µM) and inhibits binding of miR-20a, miR-26a, miR-107, miR-223 & let-7a to Ago2.
AS 1842856 is a potent and selective Foxo1 inhibitor (IC50 values are 33 nM at Foxo1 and >1 μM at Foxo3a and Foxo4)
A zwitterionic detergent useful for the solubilization of proteins including previously undetected membrane proteins. ASB-14 exhibits better protein solubilization properties than CHAPS. Also useful for solubilizing proteins for 2D-gel electrophoresis.
ASB-16 is a useful zwitterionic detergent for the solubilization of proteins including previously undetected membrane proteins. ASB-16 exhibits better protein solubilization properties than CHAPS. Also useful for solubilizing proteins for 2D-gel electrophoresis.
Atglistatin is a potent, selective, and competitive inhibitor of ATGL (IC50 = 0.7 μM). It does not inhibit hormone-sensitive lipase, monoglyceride lipase, pancreatic lipase, lipoprotein lipase, or other lysophospholipases.